158 related articles for article (PubMed ID: 3300952)
1. Successful treatment with chemotherapy and subsequent allogeneic bone marrow transplantation for myeloid blastic crisis of chronic myelogenous leukemia following advanced Hodgkin's disease.
Punt CJ; Rozenberg-Arska M; Verdonck LF
Cancer; 1987 Sep; 60(5):934-5. PubMed ID: 3300952
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic bone marrow transplantation in a patient with acute myeloid leukemia secondary to Hodgkin's disease.
de Witte T; Blacklock HA; Prentice HG; de Pauw B; Haanen C
Cancer; 1984 Apr; 53(7):1507-8. PubMed ID: 6365303
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia.
Amadori S; Picardi A; Fazi P; Testi AM; Petti MC; Montefusco E; Mandelli F
Leukemia; 1996 May; 10(5):766-8. PubMed ID: 8656669
[TBL] [Abstract][Full Text] [Related]
4. Induction of molecular remission by donor peripheral blood leukocyte therapy in patients relapsing with extramedullary blastic phase chronic myeloid leukemia after allogeneic bone marrow transplantation.
Bashey A; Shepherd S; Frankel W; Wang-Rodriguez J; Cahill T; Chamberlain M; Mason JR; Ho AD; Corringham RE
Oncol Rep; 1998; 5(1):281-5. PubMed ID: 9458334
[TBL] [Abstract][Full Text] [Related]
5. [Complete cytogenetic response obtained with unrelated donor lymphocyte infusion for relapse of chronic myeloid leukemia in blastic crisis after allogeneic bone marrow transplantation].
Fujimaki K; Maruta A; Yoshida M; Yamazaki E; Matsuzaki M; Fujisawa S; Kanamori H; Ishigatsubo Y
Rinsho Ketsueki; 2001 Mar; 42(3):204-8. PubMed ID: 11345783
[TBL] [Abstract][Full Text] [Related]
6. Accelerated and blastic phase of chronic myeloid leukemia.
Dutcher JP; Wiernik PH
Curr Treat Options Oncol; 2000 Apr; 1(1):51-62. PubMed ID: 12057061
[TBL] [Abstract][Full Text] [Related]
7. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Elmaagacli AH; Beelen DW; Schaefer UW
Bone Marrow Transplant; 1997 Dec; 20(12):1045-55. PubMed ID: 9466277
[TBL] [Abstract][Full Text] [Related]
8. Donor buffy-coat infusion and chemotherapy for leukemia in relapse after marrow transplantation.
Bogdanić V; Aurer I; Hitrec V; Boban D; Nemet D; Zupancić-Salek S; Labar B
Haematologica; 1995; 80(4):338-40. PubMed ID: 7590504
[TBL] [Abstract][Full Text] [Related]
9. Long-term remission of T-lymphoid extramedullary blast crisis of chronic myelogenous leukemia following allogeneic bone marrow transplantation.
Montefusco E; Mauro FR; Lo Coco F; Rondinelli B; Arcese W; Tabilio A; Monarca B; Alimena G; Mandelli F
Haematologica; 1990; 75(4):391-3. PubMed ID: 2276682
[TBL] [Abstract][Full Text] [Related]
10. FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia.
Martinelli G; Testoni N; Zuffa E; Visani G; Zinzani PL; Zaccaria A; Farabegoli P; Arpinati M; Amabile M; Tura S
Leuk Lymphoma; 1996 Jun; 22(1-2):173-6. PubMed ID: 8724545
[TBL] [Abstract][Full Text] [Related]
11. [A case of chronic myelogenous leukemia responding to imatinib mesilate (Glivec) after relapse of blastic crisis following allogeneic bone marrow transplantation].
Fujisawa S; Yano K; Kobayashi M
Gan To Kagaku Ryoho; 2003 Mar; 30(3):427-30. PubMed ID: 12669406
[TBL] [Abstract][Full Text] [Related]
12. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis.
Derderian PM; Kantarjian HM; Talpaz M; O'Brien S; Cork A; Estey E; Pierce S; Keating M
Am J Med; 1993 Jan; 94(1):69-74. PubMed ID: 8420302
[TBL] [Abstract][Full Text] [Related]
13. T-cell blast crisis of chronic myelogenous leukemia manifesting as a large mediastinal tumor.
Ye CC; Echeverri C; Anderson JE; Smith JL; Glassman A; Gulley ML; Claxton D; Craig FE
Hum Pathol; 2002 Jul; 33(7):770-3. PubMed ID: 12196931
[TBL] [Abstract][Full Text] [Related]
14. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.
Sacchi S; Kantarjian HM; O'Brien S; Cortes J; Rios MB; Giles FJ; Beran M; Koller CA; Keating MJ; Talpaz M
Cancer; 1999 Dec; 86(12):2632-41. PubMed ID: 10594858
[TBL] [Abstract][Full Text] [Related]
15. Extramedullary blast crisis in a patient with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic remission.
O'Brien S; Witt R; Talpaz M; Kantarjian H
Cancer; 1991 Apr; 67(7):1946-9. PubMed ID: 2004308
[TBL] [Abstract][Full Text] [Related]
16. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.
Kantarjian HM; Talpaz M; Kontoyiannis D; Gutterman J; Keating MJ; Estey EH; O'Brien S; Rios MB; Beran M; Deisseroth A
J Clin Oncol; 1992 Mar; 10(3):398-405. PubMed ID: 1740679
[TBL] [Abstract][Full Text] [Related]
17. Treatment of myeloid blastic crisis of chronic myelogenous leukemia.
Preisler HD; Raza A; Higby D; Kirshner J; Woll J; Bennett J; Winton L; Weiner R; Richman C; Golomb H
Cancer Treat Rep; 1984 Nov; 68(11):1351-5. PubMed ID: 6388833
[TBL] [Abstract][Full Text] [Related]
18. A dose intensive regimen of cytosine arabinoside and daunorubicin for chronic myelogenous leukemia in blast crisis.
Kouides PA; Rowe JM
Leuk Res; 1995 Oct; 19(10):763-70. PubMed ID: 7500655
[TBL] [Abstract][Full Text] [Related]
19. [Chemotherapy of chronic myelogenous leukemia--VP(M) regimen initiated during its chronic phase, and evaluation of MCNU in the phase of blastic crisis].
Kitajima K; Adachi T; Takahashi I; Nakada H; Osada K; Fukuda S; Ohmoto E; Aoyama S; Yorimitsu S; Sanada H
Gan To Kagaku Ryoho; 1989 Nov; 16(11):3573-9. PubMed ID: 2817908
[TBL] [Abstract][Full Text] [Related]
20. Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease.
Mundt AJ; Sibley G; Williams S; Hallahan D; Nautiyal J; Weichselbaum RR
Int J Radiat Oncol Biol Phys; 1995 Sep; 33(2):261-70. PubMed ID: 7673013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
